Concurrent Session 87: Tolerance: Antigen Presenting Cells

Karren M. Plain,Nirupama D. Verma,Giang T. Tran,Rochelle Boyd,Masaru Nomura,Christian Robinson,Suzanne J. Hodgkinson,Bruce M. Hall,Xiufen Zheng,Biao Feng,Costin Vladau,Gang Chen,Xusheng Zhang,Mengnan Li,Hongtao Sun,Motohiko Suzuki,Robert Zhong,Anthony Jevnikar,Weiping Min

2006-01-01

Abstract:1048 TREATMENT WITH SMALL INTERFERING RNA SPECIFIC FOR THE COMPLEMENT 5a RECEPTOR GENE PREVENTS RENAL ISCHEMIA-REPERFUSION INJURY. Xiufen Zheng, Biao Feng, Costin Vladau, Gang Chen, Xusheng Zhang, Mu Li, Hongtao Sun, Motohiko Suzuki, Robert Zhong, Anthony Jevnikar, Wei-Ping Min. The MultiOrgan Transplant Program, London Health Sciences Centre, London, ON, Canada; University of Western Ontario, London, ON, Canada. Background: Renal ischemia-reperfusion injury (IRI) is associated with activation of the Complement (C) system. A safer and more-specific alternative to chemical C inhibitors for transplantation therapy may be found in gene silencing. Although gene silencing strategies have had limited success in preventing liver and kidney IRI, silencing C genes for prevention of kidney IRI has not been reported. Herein, we investigated the effect C5aR siRNA in the prevention of kidney IRI. Methods: A warm ischemia mouse model was used in this study. Anti-C5aR siRNA-expressing vectors, containing a GFP reporter gene, were constructed and gene silencing potency of each construct was evaluated in vitro. Mice were injected with 50 ug of C5aR siRNA 48h before induction of ischemia. Renal ischemia was subsequently induced through clamping of the renal vein and artery. After 24h, C5aR silencing was measured in collected kidneys using real time PCR and immunohistochemical staining. Histopathological changes of kidney were evaluated by HE staining. Additionally, blood was collected to detect BUN and creatinine for assessing the ability of C5aR siRNA to prevent kidney IRI. Results:C5aR siRNA is able to silence the expression of C5aR both in vitro an in vivo. Compared to naïve controls, mice in which ischemiareperfusion (I/R) was induced showed an increased expression of C5aR in the ischemic kidney. We used a GFP reporter and fluorescence microscopy of frozen kidney sections and observed that systemically administered C5aR siRNA can be delivered into renal tissue. C5aR siRNA was observed to inhibit expression of C5aR in the kidney and treatment with C5aR siRNA prior to induction of ischemia significantly reduced levels of BUN, and serum creatinine values 24 h subsequent to I/R injury. Our results show that interfering with C5aR expression using anti-C5aR siRNA leads to a reduction in IRI, as evidenced by maintained renal function and reduced histopathological change. Lethal kidney ischemia was prevented when C5aR R siRNA was used to treat renal ischemic animals. Conclusion: Treatment with anti-C5aR siRNA inhibited complement activation and prevented renal IRI. C5aR siRNA is may be a novel therapy for transplant rejection and acute tubular necrosis.